Expanded Access [Ga-68] PSMA-11 PET Imaging
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Mayo Clinic
- 试验地点
- 1
研究概览
简要总结
In this expanded access IND study, Mayo Clinic in Rochester MN offers [Ga-68] PSMA-11 PET/CT or PET/MR imaging to patients who meet criteria.
详细描述
[Ga-68] PSMA-11 PET/CT and PET/MR imaging has been shown to allow for accurate detection of metastatic prostate cancer at the time of initial diagnosis and staging of patients with high-risk prostate cancer and at the time of biochemical recurrence. In addition, available data show superiority of metastatic lesion detection with [Ga-68] PSMA-11 PET over conventional imaging. This improved lesion detection has a direct impact on selection of anti-cancer therapy and thus may improve patient outcomes.
Under expanded access IND, enrolled patients will receive a clinical [68Ga] PSMA-11 PET/CT or PET/MR for evaluation of their cancer. Imaging exams must be deemed clinically indicated by a referring provider. Patients will be responsible for the cost of the imaging exam. Access is limited.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Current exclusion criteria for both groups includes:
- •Patients unable to sign informed consent
- •Patient with a life expectancy less than 6 months
- •Additional exclusion criteria may be added based on demand
研究者
Geoffrey Johnson
Principal Investigator
Mayo Clinic